There was some encouraging news from across the Atlantic.
News & Analysis: AnaptysBio
Perhaps no news is bad news for the ambitious biotech.
The biotech got a sharp upward shift in recommendation and target price from a prominent analyst.
Rule Breaker Investing: David's Biggest Losers Volume 6
The beaten-up biopharma provided an update that revved up interest in its pipeline.
Key clinical trial results this quarter will determine the better buy.
This antibody drug developer can be had for fire-sale prices.
These three biopharma stocks all ended in positive territory Friday after a week of double-digit declines.
Worries about a coronavirus impact don't make sense.
A pair of black swans crushed these three healthcare stocks today.